

*1103326-0282***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Cederberg et al.  
Serial No. : 08/945,425  
Filed : October 21, 1997  
For : ADMINISTRATION OF PHARMACEUTICALS  
Examiner : Desai, R.  
Group Art Unit : 1612

<b>CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. 1.8</b>	
I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office on March 8, 2002 at the facsimile number <u>703-308-7922</u> .	
John M. Genova Attorney Name	32,224 PTO Reg. No.
<u>John M. Genova</u> Signature	8 March 2002 Date of Signature

**Box AF**  
Assistant Commissioner for Patents  
Washington, D.C. 20231

ATTENTION: **Examiner R. Desai**  
FACSIMILE NO: **703-308-7922**  
DATE: **March 8, 2002**  
PAGES: **22 pages**

**INFORMATION DISCLOSURE STATEMENT  
FILED CONCURRENTLY WITH  
REQUEST FOR CONTINUED EXAMINATION**

Sir:

Applicants submit this communication in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. A Request for Continued Examination ("RCE") is being submitted concurrently with this Information Disclosure Statement as a separate paper. Applicants request consideration of the

patentability of the claimed invention in view of the documents listed on Form PTO-1449 attached herewith.

**REMARKS**

The referenced application is a CPA of U.S. Patent Application 08/945,425, which is a §371 application of PCT/SE97/01098, filed June 18, 1997. The PCT application claims priority to Swedish Patent Application No. 9602442-7, filed June 20, 1996. A final Office Action issued September 13, 2001.

In an Information Disclosure Statement ("IDS"), mailed April 7, 1999, Applicants identified the document WO 97/02020, published January 23, 1997 (the "WO publication"). In a supplemental IDS, mailed November 1, 1999, Applicants identified US 5,945,124, issued August 31, 1999 (the "'124 patent"). The WO publication corresponds to international application No. PCT/EP96/02892 which claims priority to the application underlying the '124 patent.

The following three documents cited in the attached Form PTO-1449 are related to the '124 patent and the WO publication:

- US 6,068,856, issued May 30, 2000 (the "'856 patent") is a divisional of the '124 patent;
- US 6,274,173 is a continuation of the '856 patent; and
- US 6,132,768 is related to the '124 patent stated in col. 1, lines 8-10, of the '124 patent.

In view of the foregoing, it is submitted that the documents cited on the attached Form PTO-1449 as part of this Information Disclosure Statement are substantively cumulative vis-à-vis the previously cited '124 patent and the WO publication.

**TIME OF TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

The Information Disclosure Statement transmitted herewith is being filed concurrently with a Request for Continued Examination and therefore no separate fee is due. However, authorization is hereby given to charge Account No. 23-1703 for any fcc which may be due in connection with this communication.

Dated: March 8, 2002

Respectfully submitted,

John M Genova  
John M. Genova  
Reg. No. 32,224  
Attorney for Applicants  
Customer No. 007470  
Attorney Direct Dial: (212) 819-8832